
"The increase is driven by the optimisation of production processes, the recent initiation of production at BioNTech#39;s Marburg, Germany facility, regulatory approval for six dose vials, and the expansion of our manufacturing and supplier network," BioNTech said in a statement.
from Moneycontrol Business News https://ift.tt/39t8J8p
No comments:
Post a Comment